o Lead US investor strategy and manage investor relationships, leading investor communication framework in US
capital markets
o Quickly developed a deep understanding of science in the company’s pipeline with a focus on oncology
(hematological malignancies and solid tumors) and pediatrics in a short time to lead 1x1 investor communications
o Lead US-based investment banking relationships, including equity research: Jefferies, Piper, Needham, Cantor, and
HCW: average upside of over 8x from US sell-side coverage target prices from November 2023 price levels
o Continuously monitor market and stock activity, providing regular updates (i.e., comprehensive analysis and targeted
investment communication, including competitor analysis, geopolitical/asset class considerations, key macro factors
driving market activity, etc.) to senior leadership team
o Developed a detailed quarterly shareholder analysis based on 13F filings to determine shareholder composition and IR
strategy to effectively determine future investor targeting based on successful conversion or shareholder selling
o Work closely with the R&D team to develop Company strategy on the greatest market opportunities, including pivot
in strategy to US-focused trials in specific therapy lines with the highest potential market opportunity
o Work closely with legal to ensure compliance
o Based on daily communication and comprehensive market and investor analysis from key stakeholders, partner with
the CEO and CFO to determine corporate strategy, i.e., repositioning of value drivers & cash burn to extend runway
o Lead IR-related and regulatory filing-related content creation including, but not limited to, drafting and finalizing
earnings releases, meeting minute logs, investor target strategy, investor decks, 6-K filings, investor call scripts, QA
sessions (through a database of meeting minutes created from investor and analyst communications), 20-F filings,
press releases
o Continuously plan, organize, and execute non-deal roadshows (NDRs), one-on-one investor calls/meetings, investor
R&D days, earnings calls, and major sell-side conferences across the US and Europe with 500+ investor meetings
o Continuously monitor financial model based on updated data and market projections
o Recorded presentation in BTIG's China Biotech Day fireside chat and at the Jefferies Healthcare Conference in NYC
KBP BIOSCIENCES, Princeton, NJ
A pre-IPO global, clinical-stage biopharmaceutical company focused on the development of an innovative pipeline of new
chemical entities with known mechanisms of action targeting underserved patient populations in organ protection.

o F1 SEC filing project lead, worked with legal counsel and bankers to complete the F1 SEC filing, writing the first
draft of the business section framework; diligent work led to only 20 comments from the SEC on the first filing.
o USD 75 mn Series B capital raise to fund Phase 3 study of lead asset; sourced interest from >40 public and private
equity funds, acting as lead (in Mandarin) with China-based investors; managed >15 through diligence (including CNinvestors in Mandarin); Hillhouse lead at >$50M
o Led and coordinated efforts with investment banks to form a banking syndicate for Nasdaq listing, connecting with
20+ lead investment banks and analysts to pitch the KBP story.
o Created data room for investors ahead of crossover round
o Created investor database as KBP had no prior relationships with many US-based investors prior to my joining
o Levered educational background in pharmacology & drug development to develop a deep understanding of the
science behind KBP's clinical pipeline and pitch the story to investors
o Discussions with banks and investors led to the creation of an internal FAQ to have a standard, unified internal
message when speaking to investors, business development partners, and the public at large.
o Completed statistical analysis on phase 2b topline data results in working with CDO, including sensitivity analysis,
logging eGFR, UACR, and potassium charts to determine error bars, p-values, mean, SD, etc., as this analysis was
presented to potential crossover investors and banks.
TYLER EHLER Page 2
o Developed peer company benchmarks and IPO performances to determine the key to a successful public launch
o Developed core company initiatives through analysis, including leading research on the market opportunity for
infectious diseases in China to provide evidence to support the market potential for the second lead compound in the
clinical pipeline
MARKETS GROUP, New York City
Executive forum organizer with a track record of 400+ capital introduction meetings in over 20 countries, working to link
asset managers and investors together to achieve a premium return on time and investment.

o Brokered relationships between asset managers and asset allocators (pensions ranging from 100 mn AUM to 400+ bnAUM, endowments, foundations, and insurance firms across the US), targeting portfolio managers focused on
strategies requested by asset managers (alternative beta, alternative credit, emerging markets, infrastructure, China A-Shares, fixed income, equities, disruptive technologies, multi-factor investing, etc.)
o Initiated relationships for the firm using a systematically targeted model to add >100 qualified managers per week
o Organized capital introduction meetings across the US with 100+ investors in the room and created an agenda with
eight-panel discussions per day with a goal of targeted introductions for asset managers
o Assembled and completed conference marketing materials, performance reports, questionnaires, and data
management
CEBM GROUP LTD, New York City
Largest independent Chinese institutional investment research firm offering China-based macroeconomic and equity
research.

o Oversaw US operations for CEBM, including building an institutional client base, company partnerships (localbrokerages, securities firms), brokering Chinese and North American partnerships and relationships
o Developed and executed marketing activities and executed roadshows as needed for Chinese client trips to the USA
with a goal of establishing partnerships for Chinese investors entering the US market, organizing and establishing
relationships with 5-10 US-based financial institutions per weekly visit (funds range from USD 10 bn AUM to USD850 bn AUM): brought 10 Chinese funds in the 2017 calendar year, with an average of 8-10 meetings per visit
o Retained 75% of clients after the previous Global Director left CEBM
o Responsible for 55% of total US office revenue in 2017, 85% of total US office revenue in 2018, 100% in 2019
o Reduced annual operational costs for US operations by 14.2% for the 2018 calendar year
o Wrote and distributed English research on infrastructure, real estate, banking, steel, retail, container shipping, etc.
o Developed strong relationships with local funds and asset managers in the North American market, increasing the
contact base to 250+ relevant industry contacts
CLEDOS INTERNATIONAL LTD, Hong Kong
A subsidiary of Chinney Group Ltd, a Hong Kong family office; LED Lighting Start-Up with my department focus on

o Strategy development for cannabis grow lights: led product push into the Canadian market, evaluated the market size,
benchmarking against local peers, conducted the ground interviews, and predicted target profitability
o Designed front-to-back strategy for product development, marketing, and sales strategy for the North American
customer base, leading to successful conversion of buyers in California and Colorado
o Performed analysis on grow lights to determine optimal lighting for optimal cannabis growth for producers
o Developed corporate strategy in identifying potential partners to support global marketing and sales efforts

Publicly listed Hong Kong-based investment holding company
o Rotated through departments of Hong Kong family holdings company, with a focus on the innovative investment
group
TYLER EHLER Page 3